A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT
Launched by ALPHA TAU MEDICAL LTD. · Nov 8, 2021
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
Medical records of patients that previously underwent the Alpha DaRT treatment will be reviewed by an authorized staff member.
Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include:
* Safety - assessment of late onset of Alpha DaRT related AE in patients treated with the Alpha DaRT seeds
* Efficacy -
* assessment of local recurrence rates in patients who achieved initial complete response (CR) following the Alpha DaRT treatment
* assessment of duration of response...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients previously treated with the Alpha DaRT seeds for management of either skin or oral cavity SCC
- • Available information in medical charts and records (electronic or paper)
- Exclusion Criteria:
- • None.
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is a pioneering healthcare company specializing in innovative cancer treatment solutions, particularly through its proprietary Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) technology. Focused on advancing the field of oncology, the company is dedicated to developing targeted therapies that enhance patient outcomes while minimizing side effects. With a commitment to rigorous clinical research and collaboration with leading medical institutions, Alpha Tau Medical aims to revolutionize cancer care by providing effective and efficient treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Meldola, , Italy
Petah Tikva, , Israel
Patients applied
Trial Officials
Noga Kurman, MD
Principal Investigator
Davidof Cancer Institution at Rabin Medical Center Israel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials